MEDVi GLP-1 – MEDVi sells convenient telehealth access to GLP-1 weight-loss medication, but the company is also facing FDA warning and lawsuits tied to marketing and advertising. Customer reviews on Trustpilot and the BBB repeatedly return to billing, cancellation, and pres
When people sign up for a weight-loss program through a telehealth platform, they’re usually buying more than a prescription. They’re buying time, discretion, and the feeling that someone will stay in the loop after the first order.
MEDVi positions itself around that promise—virtual visits with unlimited communication and medication shipped to the patient’s door. But in a picture that emerges from public complaints and regulatory scrutiny, the “after the signup” experience is where many users say things fall apart.
Dr. Joseph Barrera, an endocrinologist at Providence Mission Hospital, says telehealth platforms fill gaps in traditional care. He describes a demand from patients who want to lose weight but struggle with convenience, discretion, or insurance coverage. “Most [telehealth platforms] aren’t just selling medication — they’re selling accessibility and responsiveness. and in some cases. coaching. ” he says.
MEDVi is built around online treatment plans from licensed medical providers. The company focuses largely on weight management and also offers MEDVi Meals. a program that delivers pre-prepared meals to patients’ doors. Beyond weight loss. MEDVi says it has a growing portfolio of services: men’s healthcare. women’s healthcare (coming soon). supplement support (coming soon). skin care (coming soon). hair growth (coming soon). and peptide therapy (coming soon).
The platform’s core offering is GLP-1 medication. MEDVi markets both FDA-approved options and compounded versions, and Barrera draws a clear line between the two.
In his view. FDA-approved brand-name GLP-1s—such as Wegovy and Zepbound—are generally safer and more reliable because they’re standardized. studied. and regulated. Compounded GLP-1s. he says. are prepared by a pharmacy using active ingredients intended to mimic the original drug. but without the exact same FDA approval process for the final compounded product itself. “Since ingredients can vary in compounded GLP-1s, so might the results,” Barrera explains.
That distinction matters because MEDVi’s pricing and patient experience depend on which medication a provider selects.
MEDVi’s monthly costs vary by semaglutide and tirzepatide prescription and by whether the drug is brand-name or compounded. The company says no insurance is needed, and that the price a patient pays includes the medication, shipping, lab work, and telehealth support.
For brand-name GLP-1s, MEDVi lists flat monthly ranges of $1,000 to $1,400. For compounded options. the company gives lower entry pricing followed by higher ongoing rates: compounded semaglutide (injection) starts at $179 and then $299 per month; compounded semaglutide (pill) can be up to $299 per month. Compounded tirzepatide (injection) starts at $279 and then $399 per month, and compounded tirzepatide (pill) starts at $279 and then $399 per month.
MEDVi says customers can save by paying for three, six, or 12 months upfront. The company also states that brand-name medications aren’t always available through its platform, while noting that the FDA is changing its policies on compounded drugs—meaning availability could change.
On the surface. MEDVi’s pitch is straightforward: convenience and relatively lower costs compared with platforms that primarily prescribe brand-name GLP-1s. plus no standalone membership fee. Hers. for example. charges $39 for the first month and then $149 per month. according to the details presented here. with medication costing an extra $149 to $1. 899 per month depending on the medication.
But alongside the price math, MEDVi is also operating under a cloud.
The company has “recently received an FDA warning” and has been named in lawsuits tied to marketing and advertising violations. The company’s critics also keep pointing back to another concern: when a patient tries to adjust, stop, or cancel a plan, the process doesn’t match what many expected.
In a section of reported drawbacks, MEDVi’s cons include business challenges tied to the FDA warning and lawsuits, customer service and billing issues, and problems canceling plans. Many reviews describe unhelpful customer service and difficulty canceling.
Trustpilot. where MEDVi holds a rating of 4.4 out of 5 stars with more than 13. 000 reviews as of May 2026. shows a split between positive and negative experiences. Some users describe positive interactions during virtual appointments with their provider. Others—through many of the platform’s negative reviews—cite billing and prescription issues. including unsuccessful cancellation attempts and being charged even when they did not receive medication.
On the Better Business Bureau’s site, MEDVi is not accredited by the BBB and has an F rating. Negative BBB complaints mirror the Trustpilot pattern, focusing on billing and prescription issues, including failed cancellation attempts and being charged without receiving medication.
People on Reddit describe similar problems too. Some users report weight loss success, but others say they faced trouble canceling accounts, unexpected price hikes, and refusal of refunds.
MEDVi’s subscription terms appear to be part of what users may be reacting to. The company’s subscription typically increases after the first month, and its policy explicitly states that it doesn’t issue refunds unless a provider deems a patient ineligible for GLP-1s.
The way patients access treatment also follows a specific workflow. Customers do not need a prescription to sign up for MEDVi, but they do need one to receive GLP-1 medications. After signing up, patients fill out a survey to see if they qualify. If they qualify, an OpenLoop Health provider meets with them, reviews eligibility, and prescribes the medication. These providers oversee care and can adjust prescriptions if necessary.
MEDVi’s product availability is also constrained geographically. The company says it isn’t available in North Dakota, and that weight loss drugs have limitations in other states.
The internal chain of decisions—OpenLoop Health assessing eligibility and MEDVi providers prescribing medication—collides with the public complaints about billing and cancellation. Patients aren’t just waiting for an order; they’re also navigating a subscription that. according to multiple review sources. can become difficult to stop.
The sequence seems to follow a common patient rhythm: sign up for convenience, then deal with the operational details after the first month—when subscription pricing changes and when cancellation or refunds become the central issue.
MEDVi acknowledges at least one operational friction point: it says brand-name medications aren’t always available through the platform.
For people weighing alternatives, MEDVi is one of many telehealth weight-loss programs that claim to make GLP-1 access easier. The choice often comes down to whether patients prioritize cost and home delivery—or whether they’re more concerned about customer service reliability and the terms around billing. refunds. and discontinuation.
Dr. Barrera emphasizes that the medication itself is only one piece of treatment. In his experience, patients who succeed long-term usually have support systems that help them preserve muscle, sustain behavioral change, manage side effects, and handle the psychological aspects of weight loss.
Where MEDVi stands now is a blend of convenience and controversy: a telehealth model built for easy access to GLP-1 medications, paired with complaints about billing, prescription problems, and cancellation—and with an FDA warning and lawsuits for marketing and advertising violations.
That clash is likely to matter most to prospective patients at the decision point when affordability and discretion are attractive, but the real test arrives later—when they want to know whether help is still there and whether stopping is as simple as starting.
MEDVi GLP-1 weight loss telehealth semaglutide tirzepatide FDA warning Trustpilot Better Business Bureau OpenLoop Health billing complaints compounded GLP-1